We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Program Monitors HIV/AIDS Laboratories Worldwide

By LabMedica International staff writers
Posted on 09 Dec 2010
Reliable and reproducible laboratory data are essential in evaluating treatments for human immunodeficiency virus (HIV) infection and there are several dozen laboratories globally that perform such assays. More...


A contract has been awarded to Duke University Medical Center (Durham, NC, USA) to support the development, implementation, and oversight of external quality assurance programs that monitor laboratories involved in HIV and acquired immunodeficiency syndrome (AIDS) research and vaccine trials around the world.

The contract, worth up to $52.8 million over the next seven years, was awarded by the US National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), (Bethesda, MD, USA). Duke University has been requested to concentrate its work on several programs under the contract, including evaluation of processing and storage of blood from participants enrolled in NIAID supported clinical trials; evaluation of tests that measure immune responses to new therapies; coordination of efforts for new assays and new assay validation procedures, and participation in establishing and characterizing unique clade-specific HIV viral panels. The contract also calls for the creation of new blood and reagent banks and expanded resources at Duke to enable additional onsite work in processing, testing and shipping blood products, assays, and reagents world-wide.

The goals of the contract will require the creation of several new support systems. One would be the development of central web repository at the Duke Clinical Research Institute that would to track all project data, including testing and quality assurance findings. The system would track deviation from approved protocols and generate laboratory performance standards over time.

The project will be led by Thomas Denny, MSc, COO of the Duke Human Vaccine Institute. He said, "Virus panels are used to determine how well new laboratory tests perform, but some of the panels developed for this work are more than 15 years old. As a result, current panels may not be truly reflective of which virus strains are circulating in the world today as they can change over time."

Related Links:
Duke University Medical Center
National Institutes of Health



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.